



**Cohere Medicare Advantage Policy –
Computed Tomography Angiography (CTA), Head**
Clinical Guidelines for Medical Necessity Review

Version: 1
Effective Date: September 19, 2024

Important Notices

Notices & Disclaimers:

GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice. This policy may be superseded by existing and applicable Centers for Medicare & Medicaid Services (CMS) statutes.

©2024 Cohere Health, Inc. All Rights Reserved.

Other Notices:

HCPCS® and CPT® copyright 2024 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

Guideline Information:

Specialty Area: Diagnostic Imaging

Guideline Name: Cohere Medicare Advantage Policy - Computed Tomography Angiography (CTA), Head

Date of last literature review: 9/16/2024

Document last updated: 9/18/2024

Type: Adult (18+ yo) | Pediatric (0-17 yo)

Table of Contents

Important Notices	2
Table of Contents	3
Medical Necessity Criteria	4
Service: Computed Tomography Angiography (CTA), Head	4
Benefit Category	4
Related CMS Documents	4
Recommended Clinical Approach	4
Evaluation of Clinical Benefits and Potential Harms	4
Medical Necessity Criteria	6
Indications	6
Non-Indications	11
Disclaimer on Radiation Exposure in Pediatric Population	12
Procedure Codes (CPT/HCPCS)	13
Medical Evidence	14
References	15
Clinical Guideline Revision History/Information	20

Medical Necessity Criteria

Service: Computed Tomography Angiography (CTA), Head

Benefit Category

Not applicable.

Related CMS Documents

Please refer to the [CMS Medicare Coverage Database](#) for the most current applicable CMS National Coverage.

- There are no NCDs and/or LCDs for CTA Head.

Recommended Clinical Approach

Computed tomography angiography (CTA) and CT venography (CTV) of the head help detect and characterize vascular disease and anatomy relevant to treating extravascular disorders. CTA may be used as the primary modality for detecting disease, as an adjunctive tool for characterizing a known disease, or to assess changes over time.¹ Magnetic resonance angiography (MRA) or magnetic resonance venography (MRV) is the preferred imaging study due to the lack of ionizing radiation.

Evaluation of Clinical Benefits and Potential Harms

Cohere Health uses the criteria below to ensure consistency in reviewing the conditions to be met for coverage of CTA of the head. This process helps to prevent both incorrect denials and inappropriate approvals of medically necessary services. Specifically, limiting incorrect approvals reduces the risks associated with unnecessary procedures, such as complications from surgery, infections, and prolonged recovery times.

The potential clinical harms of using these criteria may include:

- Inherent risk of procedure: There are inherent risks of imaging, including cumulative radiation exposure, contrast, allergy, nephrotoxicity, and contrast extravasation into surrounding tissues.²⁻⁵
- Potential danger to pregnancy: CT imaging completed during

pregnancy confers a dose of ionizing radiation to the fetus and is generally only utilized when the potential benefits of this specific imaging modality outweigh the risks to the pregnancy.⁶ Fetal risk includes fetal demise, intrauterine growth restriction, microcephaly, delayed intellectual development, risk of childhood cancer, and fetal thyroid injury.⁶

- Increased healthcare costs and complications from the inappropriate use of additional interventions.⁷

The clinical benefits of using these criteria include:

- Accuracy: CTA of the head is effective in diagnosing acute ischemic stroke. A study assessing acute stroke imaging found that CTA compared to non-contrast CT, increased the diagnosis of acute ischemic stroke.⁸
- Patient outcomes: CTA has a low risk of allergic reaction and contrast-induced neuropathy; adverse patient outcomes are minor.⁹
- Early diagnosis: Improved resolution of CTA may lead to early diagnosis of vascular abnormalities.¹⁰
- Enhanced overall patient satisfaction and healthcare experience.

This policy includes provisions for expedited reviews and flexibility in urgent cases to mitigate risks of delayed access. Evidence-based criteria are employed to prevent inappropriate denials, ensuring that patients receive medically necessary care. The criteria aim to balance the need for effective treatment with the minimization of potential harms, providing numerous clinical benefits in helping avoid unnecessary complications from inappropriate care.

In addition, the use of these criteria is likely to decrease inappropriate denials by creating a consistent set of review criteria, thereby supporting optimal patient outcomes and efficient healthcare utilization.

Medical Necessity Criteria

Indications

→ **Computed tomography angiography (CTA), head** is indicated if **ANY** of the following is **TRUE**:

- ◆ Neoplastic conditions including surgical and radiation therapy localization, planning, and neuronavigation to delineate the

vascular anatomy (e.g., tumor is in the vicinity or encases a major artery or occludes major vein)¹; **OR**

- ◆ Trauma-related conditions as indicated by **ANY** of the following:
 - Head trauma with suspected intracranial arterial injury due to clinical risk factors or positive findings on prior imaging¹¹; **OR**
 - Blunt cerebrovascular injury (BCVI) is suspected based on the mechanism and location of trauma (CT neck is also indicated with CT head)¹²; **OR**
 - Traumatic vascular injuries¹; **OR**
 - Suspected carotid or vertebral artery dissection secondary to trauma; **OR**
- ◆ Vascular conditions, known or suspected, including **ANY** of the following:
 - Aneurysm with **ANY** of the following¹³⁻¹⁸:
 - Screening for cerebral artery aneurysm when **ANY** of the following is **TRUE**¹⁹⁻²⁷:
 - ◆ Autosomal dominant polycystic kidney disease (adults); **OR**
 - ◆ The patient has two or more first-degree relatives (parent, brother, sister, or child) with a history of intracranial aneurysm; **OR**
 - ◆ The patient is symptomatic with one first-degree relative who has a history of intracranial aneurysm^{13-15,28}; **OR**
 - ◆ Fibromuscular dysplasia; **OR**
 - ◆ Loeys-Dietz syndrome; **OR**
 - ◆ Spontaneous coronary arteries dissection (SCAD); **OR**
 - ◆ Known aortic coarctation (after age 10); **OR**
 - **ANY** of the following:
 - ◆ Diagnosis of intracranial hemorrhage; **OR**
 - ◆ Diagnosis of subarachnoid hemorrhage; **OR**
 - ◆ Intracerebral hemorrhage, known or suspected²⁹; **OR**
 - ◆ The patient has a history of subarachnoid hemorrhages¹⁴; **OR**
 - Cervical bruit or thrill with suspicion of neck carotid stenosis; **OR**

- Headache with **ANY** of the following:
 - Acute onset worst/thunderclap headache³⁰; **OR**
 - New onset or pattern during pregnancy or peripartum period; **OR**
 - Associated with exercise, exertion, Valsalva, or sexual activity; **OR**
- Intracranial arterial dissection, suspected; **OR**
- Intracranial occlusive disease (arterial or venous), suspected³¹; **OR**
- Intracranial hypertension (idiopathic), suspected; **OR**
- Pseudoaneurysm¹; **OR**
- Recent stroke, up to 6 months (remote history is not an indication unless recent TIA episodes)¹; **OR**
- Cranial neuropathy as indicated by **ANY** of the following and prior imaging is suspicious for a vascular pathology (e.g., aneurysm, arteriovenous fistulas [AVF])^{1,16-17}:
 - Lower cranial nerve palsies, weakness or paralysis (CN IX-XII) (i.e., glossopharyngeal neuralgia); **OR**
 - Unilateral isolated weakness or paralysis of the tongue (hypoglossal nerve, CN XII); **OR**
 - Refractory trigeminal neuralgia when done for surgical planning; **OR**
 - Isolated third nerve palsy (oculomotor) with pupil involvement to evaluate for aneurysm; **OR**
 - Any combination or isolated involvement of cranial nerves where prior imaging is suspicious for vascular pathology; **OR**
- Acute or recent unexplained intracranial hemorrhage¹; **OR**
- Atherosclerotic stenosis or occlusive disease, including suspected vasospasm or thromboembolism with **ANY** of the following¹:
 - Patient has documented symptoms suggestive of stroke or TIA; **OR**
 - Based on prior imaging; **OR**
- Vasculopathy that is non-atherosclerotic, non-inflammatory (e.g., radiation vasculopathy) and suspected on prior imaging (e.g., CT, MRI)¹; **OR**
- The patient has **ANY** of the following:
 - Abnormal neurologic signs; **OR**

- Fever; **OR**
- Visual disturbance; **OR**
- Vertigo; **OR**
- Weight loss; **OR**
- Vascular malformation and fistula based on prior imaging¹; **OR**
- Cerebrovascular disease in a patient age 18 or older including **ANY** of the following¹⁸:
 - Acute subarachnoid hemorrhage (SAH), suspected or known on CT; **OR**
 - Central nervous system (CNS) vasculitis, suspected; **OR**
 - Cerebral aneurysm (treated or untreated), known; **OR**
 - Cerebral vasospasm, suspected; **OR**
 - High-flow vascular malformation (AVM/AVF), known; **OR**
 - Aneurysmal SAH in a younger patient who is at-risk of de novo aneurysm formation; **OR**
 - The patient has **ANY** of the following:
 - ◆ Moyamoya disease; **OR**
 - ◆ Bicuspid aortic valve; **OR**
 - ◆ Aortic aneurysm; **OR**
 - ◆ Coarctation of the aorta; **OR**
- Cerebrovascular disease in a patient age 17 or younger and **ANY** of the following is **TRUE**³⁰:
 - Acute stroke is suspected with **ANY** of the following:
 - ◆ Non-sickle-cell related with new focal fixed or worsening neurologic deficit lasting less than 24 hours from last seen normal state and there are no contraindications to emergent intervention; **OR**
 - ◆ Known or suspected arteriopathy or moyamoya¹⁷⁻¹⁸; **OR**
 - ◆ Known or suspected central nervous system vasculitis; **OR**
 - ◆ Known or suspected low- or high-flow vascular anomaly; **OR**
 - ◆ The patient is not a candidate for emergent intervention; **OR**

- Acute subarachnoid hemorrhage (SAH), suspected or known on CT; **OR**
- Spontaneous cervicocranial arterial dissection based on clinical or imaging findings. (CTA head and neck ordered together); **OR**
- Nontraumatic intracranial hemorrhage (hematoma) of unknown etiology found on CT or MRI and additional imaging study is needed; **OR**
- Nontraumatic SAH detected by non-contrast CT; **OR**
- Vertebrobasilar insufficiency (VBI) as indicated by **ANY** of the following^{29,31}:
 - Abnormal neurologic examination is consistent with central vertigo; **OR**
 - Associated with other brainstem neurologic deficits; **OR**
 - HINTS (Head Impulse-Nystagmus-Test of Skew) examination is consistent with central vertigo; **OR**
 - Neurological symptoms (central vertigo); **OR**
- ◆ For evaluation of **ANY** of the following miscellaneous pathologies when prior testing has failed:
 - Headache with an unrevealing MRI and **ANY** of the following is **TRUE**:
 - Persistent in nature; **OR**
 - Undifferentiated; **OR**
 - Unexplained; **OR**
 - Pulsatile tinnitus (unilateral or bilateral) as evidenced by **ANY** of the following^{1,32-33}:
 - Localized to one ear (prior testing not required); **OR**
 - Focal neurological abnormalities (consider MRI brain internal auditory canal [IAC] protocol first); **OR**
 - Asymmetric hearing loss (consider MRI brain internal auditory canal [IAC] protocol first); **OR**
 - Visual impairment including **ANY** of the following³²:
 - Isolated third nerve palsy (oculomotor) with pupil involvement to evaluate for aneurysm; **OR**
 - Suspected venous thrombosis (e.g., dural sinus thrombosis) when MRV is contraindicated or cannot be performed; **OR**
- ◆ Preoperative assessment of vascular anatomy or pathology; **OR**

- ◆ Post-treatment follow-up to monitor treatment result and surveillance of vascular condition; **OR**
- ◆ Congenital conditions or anomalies including vascular abnormality associated with chronic anemic conditions (e.g., sickle cell disease) (MRA head is preferred in pediatric patients)³⁵⁻³⁶; **OR**

→ **Computed tomography venography (CTV), head** is indicated if **ANY** of the following is **TRUE**:

- ◆ Ultrasound and CT venography (CTV) are contraindicated or inconclusive (e.g., body habitus for ultrasound, anaphylactic reaction due to IV contrast reaction, pregnancy, pediatric); **OR**
- ◆ **ANY** of the following is **TRUE**:
 - Vascular conditions, known or suspected, including **ANY** of the following:
 - Venous/dural sinus abnormalities such as **ANY** of the following:
 - ◆ Acquired thrombosis/occlusion; **OR**
 - ◆ Venous sinus stenosis; **OR**
 - Large vein injury secondary to trauma; **OR**
 - Vascular invasion or displacement by tumor; **OR**
 - Headache with **ANY** of the following:
 - New onset or pattern during pregnancy or peripartum period; **OR**
 - Headache with features of intracranial hypertension (e.g., papilledema, pulsatile tinnitus, visual symptoms worse on Valsalva)³⁰; **OR**
 - Initial diagnostic, one-time pre or one-time post-treatment evaluation for treatment planning or evidence of clinical concern for vascular malformation.

→ **Repeat imaging** (defined as repeat request following recent imaging of the same anatomic region with the same modality), in the absence of established guidelines, will be considered reasonable and necessary if **ANY** of the following is **TRUE**:

- ◆ New or worsening symptoms, such that repeat imaging would influence treatment; **OR**
- ◆ One-time clarifying follow-up of a prior indeterminate finding; **OR**

- ◆ In the absence of change in symptoms, there is an established need for monitoring which would influence management.

Non-Indications

→ **Computed tomography angiography (CTA) or computed tomography venography (CTV), head**, is not considered appropriate if **ANY** of the following is **TRUE**³⁷:

- ◆ If contrast is used, history of anaphylactic allergic reaction to iodinated contrast media.

*NOTE: The referring professional and radiologist should discuss the risks and benefits of contrast media administration, including possible prophylaxis, in patients with chronic or worsening kidney disease or severe renal failure.

**NOTE: CT in pregnant patients should be requested at the discretion of the ordering provider and obstetric care provider.

***NOTE: CT in patients with claustrophobia should be requested at the discretion of the ordering provider.

Disclaimer on Radiation Exposure in Pediatric Population

Due to the heightened sensitivity of pediatric patients to ionizing radiation, minimizing exposure is paramount. At Cohere, we are dedicated to ensuring that every patient, including the pediatric population, has access to appropriate imaging following accepted guidelines. Radiation risk is dependent mainly on the patient's age at exposure, the organs exposed, and the patient's sex, though there are other variables. The following technical guidelines are provided to ensure safe and effective imaging practices:

Radiation Dose Optimization: Adhere to the lowest effective dose principle for pediatric imaging. Ensure that imaging protocols are specifically tailored for pediatric patients to limit radiation exposure.^{4,38}

Alternative Modalities: Prioritize non-ionizing imaging options such as ultrasound or MRI when clinically feasible, as they are less likely to expose the patient to ionizing radiation. For instance, MRI or ultrasound should be considered if they are more likely to provide an accurate diagnosis than CT, fluoroscopy, or radiography.^{4,38}

Cumulative Dose Monitoring: Implement systems to track cumulative

radiation exposure in pediatric patients, particularly for those requiring multiple imaging studies. Regularly reassess the necessity of repeat imaging based on clinical evaluation.^{4,38}

CT Imaging Considerations: When CT is deemed the best method for achieving a correct diagnosis, use the lowest possible radiation dose that still yields reliable diagnostic images.^{4,38}

Cohere Imaging Gently Guideline

The purpose of this guideline is to act as a potential override when clinically indicated to adhere to Imaging Gently and Imaging Wisely guidelines and As Low As Reasonably Possible (ALARA) principles.

Level of Care Criteria

Inpatient and Outpatient

Procedure Codes (CPT/HCPCS)

CPT/HCPCS Code	Code Description
70496	Computed tomographic angiography (CTA), head; with contrast material(s), including non-contrast images, if performed, and image postprocessing

Medical Evidence

Tu et al. (2022) conducted a retrospective review on the utilization of head and neck computed tomography angiography (CTA) in the emergency department (ED). Head and neck CTA in the ED has shown a disproportionate increase compared to other neuroimaging examinations. The study contrasted utilization and the frequency of communicating non-routine results across different patient chief concerns. The study identified the top 50 primary concerns leading to the most CTA examinations. A total of 17903 CTAs for 833 distinct chief concerns were included, which accounts for 2.5% of 708,145 ED visits. The rates of ordering and communication of non-standard results exhibit significant variability across different chief concerns. Approximately half of the non-standard communications made by radiologists pertain to acute indications. Understanding the trends in ordering head and neck CTA and communicating non-standard results can aid in refining patient selection and enhancing radiologist interactions in the ED.³⁹

Schenk et al. (2021) report on a retrospective review of stroke in young adults. The use of CTA head and neck diagnostic yield for anterior circulation ischemic stroke evaluation is discussed. The review included adults aged 18–50 who presented to the Mayo Clinic Rochester ED. Carotid dissection is a predominant cause of anterior circulation ischemic stroke, as evidenced by findings on CTA. Studies found that carotid webs were infrequent in the patients studied, while carotid atherosclerosis was relatively rare – the presence of carotid webs, understanding their potential to trigger recurrent strokes. The authors did not cite a significant disparity in the prevalence of carotid atherosclerosis between the symptomatic and asymptomatic sides. Clinicians can recognize high-risk morphological attributes of carotid plaque observed on CT angiography, even in cases with no discernible stenosis.⁴⁰

Heit et al. (2016) conducted an 11-year single-center retrospective review to analyze the yield of digital subtraction angiography (DSA) in patients with subarachnoid hemorrhage. DSA reveals vascular abnormalities in 13% of patients who initially test negative for subarachnoid hemorrhage (SAH) on CTA. Upon subsequent DSA, aneurysms or pseudoaneurysms are found in 4% of cases. Utilization of DSA may be appropriate for all patients with SAH-negative CT scans. To aid the clinician, the type of SAH pattern observed with DSA may offer clues to the underlying cause of the hemorrhage.⁴¹

References

1. American College of Radiology (ACR), American Society of Neuroradiology (ASNR), Society for Pediatric Radiology (SPR). ACR–ASNR–SPR practice parameter for the performance and interpretation of cervicocerebral computed tomography angiography (CTA) – resolution 42. Updated 2020. Accessed August 1, 2024. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CervicoCerebralCTA.pdf>.
2. Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy. *Life Sci*. 2020 Oct 15;259:118379.
3. Rudnick MR, Leonberg-Yoo AK, Litt HI, Cohen RM, Hilton S, Reese PP. The controversy of contrast-induced nephropathy with intravenous contrast: what is the risk? *AJKD*. 2020 Jan 1;75(1):105–13.
4. The Image Gently Alliance. Procedures – image gentle and CT scans. Updated 2014. Accessed June 26, 2024. <https://www.imagegently.org/Procedures/Computed-Tomography>.
5. Summers LN, Harry ML, Colling KP. Evaluating our progress with trauma transfer imaging: repeat CT scans, incomplete imaging, and delayed definitive care. *Emerg. Radiol*. 2021 Oct;28(5):939–48.
6. Nguyen T, Bhosale PR, Cassia L, Surabhi V, Javadi S, Milbourne A, Faria SC. Malignancy in pregnancy: Multimodality imaging and treatment. *Cancer*. 2023 May 15;129(10):1479–91.
7. Kjelle E, Brandsæter IØ, Andersen ER, et al. Cost of low-value imaging worldwide: A systematic review. *Appl. Health Econ. Health Policy*. 2024 Mar 1:1–7.
8. Douglas V, Shamy M, Bhattacharya P. Should CT angiography be a routine component of acute stroke imaging? *Neurohospitalist*. 2015 Jul;5(3):97–8. doi: 10.1177/1941874415588393. PMID: 26288667; PMCID: PMC4530427.
9. Probst MA, Hoffman JR. Computed tomography angiography of the head is a reasonable next test after a negative noncontrast head computed tomography result in the emergency department evaluation of subarachnoid hemorrhage. *Ann Emerg Med*. 2016 Jun;67(6):773–774. doi: 10.1016/j.annemergmed.2014.03.009. PMID: 27217126; PMCID: PMC5338565.
10. Ghorishi A, Alayon A, Ghaddar T, Kandah M, Amundson PK. MR and CT angiography in the diagnosis of vasculitides. *BJR Open*. 2023 Sep

25;5(1):20220020. doi: 10.1259/bjro.20220020. PMID: 37953869; PMCID: PMC10636354.

11. Expert Panel on Neurological Imaging, Shih RY, Burns J, et al. ACR appropriateness criteria – head trauma: 2021 update. *J Am Coll Radiol*. 2021 May;18(5S):S13–S36. doi: 10.1016/j.jacr.2021.01.006. PMID: 33958108.
12. Expert Panel on Neurological Imaging and Musculoskeletal Imaging, Beckmann NM, West OC, et al. ACR appropriateness criteria – suspected spine trauma. *J Am Coll Radiol*. 2019 May;16(5S):S264–S285. doi: 10.1016/j.jacr.2019.02.002. PMID: 31054754.
13. Rinkel GJ, Ruigrok YM. Preventive screening for intracranial aneurysms. *Int J Stroke*. 2022 Jan;17(1):30–36. doi: 10.1177/17474930211024584. PMID: 34042530; PMCID: PMC8739572.
14. Emorrhage U, Tudy S, Rou G. Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage. *N Engl J Med*. 1999; 28;341(18):1344–50. doi: 10.1056/NEJM199910283411803. PMID: 10536126.
15. Brown Jr RD, Huston J, Hornung R, et al. Screening for brain aneurysm in the Familial Intracranial Aneurysm study: Frequency and predictors of lesion detection. *J Neurosurg*. 2008 Jun;108(6):1132–8. doi: 10.3171/JNS/2008/108/6/1132. PMID: 18518716; PMCID: PMC4190025.
16. Expert Panel on Neurological Imaging, Rath TJ, Policeni B, et al. ACR appropriateness criteria – cranial neuropathy. Updated 2022. Accessed August 1, 2024. <https://acsearch.acr.org/docs/69509/Narrative/>.
17. Expert Panel on Neurological Imaging, Pannell JS, Corey AS, et al. ACR appropriateness criteria – cerebrovascular diseases (stroke and stroke-related conditions). Published 2023. Accessed August 1, 2024. <https://acsearch.acr.org/docs/3149012/Narrative>.
18. Expert Panel on Neurologic Imaging, Ledbetter LN, Burns J, et al. ACR appropriateness criteria – cerebrovascular diseases, aneurysm, vascular malformation, and subarachnoid hemorrhage. *J Am Coll Radiol*. 2021 Nov;18(11S):S283–S304. doi: 10.1016/j.jacr.2021.08.012. PMID: 34794589.
19. Hayes SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection: current state of the science: a Scientific Statement from the American Heart Association. *Circulation*. 2018;137(19):e523–e557. doi:10.1161/cir.0000000000000564
20. Hitchcock E, Gibson WT. A review of the genetics of intracranial berry aneurysms and implications for genetic counseling. *J Genet Couns*. 2017;26(1):21–31. doi:10.1007/s10897-016-0029-8

21. Jung WS, Kim JH, Ahn SJ, et al. Prevalence of intracranial aneurysms in patients with aortic dissection. *AJNR Am J Neuroradiol*. 2017;38(11):2089–2093. doi:10.3174/ajnr.A5359
22. Egbe AC, Padang R, Brown RD, et al. Prevalence and predictors of intracranial aneurysms in patients with bicuspid aortic valve. *Heart*. 2017;103(19):1508–1514. doi:10.1136/heartjnl-2016-311076
23. Rouchaud A, Brandt MD, Rydberg AM, et al. Prevalence of intracranial aneurysms in patients with aortic aneurysms. *AJNR Am J Neuroradiol*. Sep 2016;37(9):1664–8. doi:10.3174/ajnr.A4827
24. Pickard SS, Prakash A, Newburger JW, Malek AM, Wong JB. Screening for intracranial aneurysms in coarctation of the aorta: a decision and cost-effectiveness analysis. *Circ Cardiovasc Qual Outcomes*. 2020;13(8):e006406. doi:10.1161/circoutcomes.119.006406
25. Xu HW, Yu SQ, Mei CL, Li MH. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. *Stroke*. 2011;42(1):204–6. doi:10.1161/strokeaha.110.578740
26. Malhotra A, Wu X, Matouk CC, Forman HP, Gandhi D, Sanelli P. MR angiography screening and surveillance for intracranial aneurysms in autosomal dominant polycystic kidney disease: a cost-effectiveness analysis. *Radiology*. 2019;291(2):400–408. doi:10.1148/radiol.2019181399
27. Flahault A, Joly D. Screening for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. *Clin J Am Soc Nephrol*. Aug 7 2019;14(8):1242–1244.
28. Bederson JB, Awad IA, Wiebers DO, et al. Recommendations for the management of patients with unruptured intracranial aneurysms: A statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke*. 2000;31(11):2742–50. doi: 10.1161/01.str.31.11.2742. PMID: 11062304.
29. Expert Panel on Neurologic Imaging, Wang LL, Thompson TA, et al. ACR appropriateness criteria – dizziness and ataxia. Published 2023. Accessed August 1, 2024. <https://acsearch.acr.org/docs/69477/Narrative/>.
30. Expert Panel on Pediatric Imaging, Robertson RL, Palasis S, et al. ACR appropriateness criteria – cerebrovascular disease (child). *J Am Coll Radiol*. 2020 May;17(5S):S36–S54. doi: 10.1016/j.jacr.2020.01.036. PMID: 32370977.
31. Expert Panel on Neurologic Imaging, Sharma A, Kirsch CFE, et al. ACR appropriateness criteria – hearing loss and/or vertigo. Published 2018.

Accessed August 1, 2024.

<https://acsearch.acr.org/docs/69488/Narrative/>.

32. Expert Panel on Neurological Imaging, Jain V, Policeni B, et al. ACR appropriateness criteria – tinnitus: 2023 update. *J Am Coll Radiol*. 2023 Nov;20(11S):S574–S591. doi: 10.1016/j.jacr.2023.08.017. PMID: 38040471.
33. Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: Tinnitus. *Otolaryngol Head Neck Surg*. 2014 Oct;151(2 Suppl):S1–S40. doi: 10.1177/0194599814545325. PMID: 25273878.
34. Expert Panel on Neurologic Imaging, Kennedy TA, Corey AS, et al. ACR appropriateness criteria – orbits, vision, and visual loss. *J Am Coll Radiol*. 2018 May;15(5S):S116–S131. doi: 10.1016/j.jacr.2018.03.023. PMID: 29724415.
35. Mallon D, Doig D, Dixon L, et al. Neuroimaging in sickle cell disease: A review. *J Neuroimaging*. 2020 Nov;30(6):725–735. doi: 10.1111/jon.12766. PMID: 33463866.
36. Sivaraju L, Mani S, Prabhu K, et al. Three-dimensional computed tomography angiographic study of the vertebral artery in patients with congenital craniovertebral junction anomalies. *Eur Spine J*. 2017 Apr;26(4):1028–1038. doi: 10.1007/s00586-016-4580-7. PMID: 27137997.
37. Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: Consensus statements from the American College of Radiology and the National Kidney Foundation. *Radiology*. 2020;294(3):660–668. doi: 10.1148/radiol.2019192094. PMID: 33015613; PMCID: PMC7525144.
38. National Cancer Institute. Radiation risks and pediatric computed tomography (CT): A guide for health care. Updated September 4, 2018. Accessed August 1, 2024. National Cancer Institute. Radiation risks and pediatric computed tomography (CT): A guide for health care. Updated September 4, 2018. Accessed June 26, 2024. <https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/pediatric-ct-scans>.
39. Tu LH, Malhotra A, Venkatesh AK, et al. Head and neck CTA utilization: Analysis of ordering frequency and nonroutine results communication, with focus on the 50 most common emergency department clinical presentations. *AJR Am J Roentgenol*. 2022 Mar;218(3):544–551. doi: 10.2214/AJR.21.26543. PMID: 34585611.
40. Schenk WB, Brinjikji W, Larson AS, et al. Diagnostic yield of neck CT angiography in young adults with anterior circulation ischemic stroke: A community based study. *Neurohospitalist*. 2021 Apr;11(2):119–124. doi: 10.1177/1941874420974542. PMID: 33791054; PMCID: PMC7958676.

41. Heit JJ, Pastena GT, Nogueira RG, et al. Cerebral angiography for evaluation of patients with CT angiogram-negative subarachnoid hemorrhage: An 11-year experience. *AJNR Am J Neuroradiol*. 2016 Feb;37(2):297-304. doi: 10.3174/ajnr.A4503. PMID: 26338924; PMCID: PMC7959954.

Clinical Guideline Revision History/Information

Original Date: September 19, 2024

Review History

Review History		